Editorial: Senate should retain essence of bill on "pay for delay" deals

The Senate should stand by a House bill that would curb "pay for delay" deals between brand-name and generic-drug companies in order to save consumers billions of dollars and reduce the federal budget deficit, according to this New York Times editorial. House lawmakers passed the legislation last week with compromise language that would allow companies to overcome a presumption deeming such agreements illegal.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI